1. Home
  2. CGTX

CGTX

Cognition Therapeutics Inc.

Logo Cognition Therapeutics Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-23-2024 1:31pm EST

$
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.

Founded: 2007 Country:
United States
United States
Employees: N/A City: PITTSBURGH
Market Cap: 71.8M IPO Year: 2021
Target Price: $6.67 AVG Volume (30 days): 204.8K
Analyst Decision: Strong Buy Number of Analysts: 3
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -0.86 EPS Growth: N/A
52 Week Low/High: $0.90 - $3.49 Next Earning Date: 05-02-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

Share on Social Networks:

Stock Insider Trading Activity of Cognition Therapeutics Inc. (CGTX)

Name Ticker Relationship Date Transaction Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Ricciardi Lisa CGTX CEO & President Mar 14 '24 Buy $1.75 5,700 $9,975.00 291,345 SEC Form 4